Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909254 | 0.87 | GAA (0.51) | GAAHPGDGRM5HRH3 | |
| SCHEMBL24080818 | 0.76 | GAA (0.65) | GAAHPGDGRM5HRH3GABRA5 | |
| SCHEMBL5909077 | 0.76 | GAA (0.57) | GAAHPGDGRM5HRH3GABRA5 | |
| SCHEMBL5909226 | 0.73 | GAA (0.63) | GAAHPGDGRM5HRH3GABRA5 | |
| SCHEMBL5909293 | 0.73 | GAA (0.63) | GAAHPGDGRM5HRH3GABRA5 | |
| SCHEMBL5909188 | 0.73 | GAA (0.63) | GAAHPGDGRM5HRH3GABRA5 | |
| SCHEMBL5909260 | 0.72 | HPGD (0.61) | GAAHPGDGRM5HRH3GABRA5 | |
| SCHEMBL5909301 | 0.72 | GAA (0.61) | GAAHPGDGRM5HRH3GABRA5 | |
| SCHEMBL5909298 | 0.71 | GAA (0.53) | GAAHPGDGRM5HRH3GABRA5 | |
| SCHEMBL5909073 | 0.71 | GAA (0.50) | GAAHPGDGRM5HRH3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | claimed |
| US-20030195192-A1 | Nicotinamides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | claimed |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | HAVIV FORTUNA | 2006-02-09 | — | — | US | disclosed |
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | disclosed |
| US-20030195192-A1 | Nicotinamides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | GAA 1798/4885HPGD 261/4885GRM5 3409/4885 |
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | GAA 1798/4885HPGD 261/4885GRM5 3409/4885 |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | FLT4, KDR, FLT1 | GAA 1379/4885HPGD 190/4885GRM5 2486/4885 |
| US-20030195192-A1 | Nicotinamides having antiangiogenic activity | NAMPT, NNT, SIRT1 | GAA 1205/4885HPGD 45/4885GRM5 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.